当前位置:公众访问 >页面
简体中文 / English
1.Screening
1.1.Inclusion criteria

nodule with high insufficient rate

nodule with macrocalcification

US assessment accords with FNA criteria recommended by C-TIRADS

Yes
/
No

Thyroid US indicates thyroid nodule.

Yes

Age ≥ 18 years old

Yes

Informed consent

Yes

1.2.Exclusion criteria

Patients unable to cooperate for FNA or CEUS

No

Active infectious focus on cervical skin

No

Pregnancy

No

Severe abnormality of coagulation function

No

Severe abnormality of heart function or lung function

No

Refuse to CEUS

No

Allergic to lidocaine or SonoVue

No

2.Preoperative indications
2.1.General information

Date for signing informed consent

2023-06-25

Telephone

18820536187

Sex

Male

Birthday

1962-04-04

Registration number

0001408431

2.2.Preoperative examination

Anteroposterior diameter

5 mm

Coagulation function

Yes

transverse diameter

6 mm

Routine blood test

Yes

Location of target thyroid nodule

right lobe

VCs function evaluated by TLUSG

unassessable

Ultrasonic diagnose

甲状腺癌

Rank of C-TIRADS

4b

Score of C-TIRADS

2

Rank of ACR TI-RADS

5

Score of ACR TI-RADS

9

Solid component of sheet-like strong echo (%)

20

Strong echo within nodule

punctate
/
Sheet-like

acoustic halo

No

border

angled

edge

clear

echo

hypoecho

Solid component (%)

100

Upper and lower diameter

6 mm

3.Intraoperative indications
3.1.Time of aspiration

End time

15:56

Start time

15:42

Date of aspiration

2023-06-25

3.2.Contrast-enhance indication (CEUS-FNA group)

Injection of SonoVue during FNA

No

Ratio of enhancement

-

No enhancement

No

Dosage of SonoVue

-

3.3.Progression of operation

Use of negative pressure

No

Aspiration times

4

FNA approach

lateral approach

Aspiration needle

Italy 23G

Patient compliance

good

Dosage of local anaesthesics

5 ml

other local anaesthesics

-

Local anesthesia

2% lidocaine

Machine

GE logiq E9

Sample capacity

a little

Grittiness

Yes

Quality of nodule

solid

Pressure

- ml

3.4.Intraoperative instant complication

vocal cord mobility assessment by ultrasound

appearance

extend of hematoma (before patient departure)

Aspiration related acute hypersensitivity reaction

No

visible hemorrhage by CDFI 30 minutes after FNA

Horner syndrome

No

methods

Vagal nerve syndrome

No

extend of hematoma (once after FNA)

Voice change

No

visible for bleeding by CDFI

Haemorrhage

No

location

Painful when leave interventional room

Yes

Analgesic

No

VAS score

-

Painful

No

Allergic to contrast agent

No

whether the voice recovers when the patient leaves

methods

4.Follow-up one week after aspiration
4.1.Postoperative cytopathology

Whether sample capacity is enough

Pathological number

Cytopathology classification

Number of observable follicular epithelial cell clusters in specimen

4.15.Physical Sbility Examination
5.Adverse events
1.Adverse events

Record of adverse events

6.Follow-up 2
7.Follow-up 3
8.Management system of participants
9.Speciman management system
10.Data management system
11.ADR/ADE management system
12.Madicine management system
13.Instruments management system
14.SOPs
14.1.Treatment SOP
14.2.Nursing SOP
14.3.Specimen collection SOP
15.Research team
15.1.Institutions
15.2.Researchers
16.Design, Methods
16.1.Calculation of sample size